BC Innovations | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
BC Extra | Jun 10, 2019
Company News

Tilos takeout sees Merck tapping TGFβ to solve checkpoint resistance

In its ongoing quest to find combinations for Keytruda pembrolizumab, Merck is acquiring two-year-old Tilos for its ability to modulate TGFβ, a target that’s been gaining interest on the back of clinical data in immuno-oncology,...
BC Week In Review | Mar 22, 2019
Company News

argenx gets first milestone payment from AbbVie for immuno-oncology therapy

AbbVie started a Phase I trial of ABBV-151 to treat solid tumors, triggering a $30 million milestone payment to argenx. AbbVie Inc. (NYSE:ABBV) exercised an option in 2018 to exclusively license the antibody targeting leucine-rich...
BC Week In Review | Aug 31, 2018
Company News

AbbVie exercises option for argenx cancer candidate

AbbVie Inc. (NYSE:ABBV) exercised an option for exclusive, worldwide rights to develop and commercialize ARGX-115 from argenx S.E. (Euronext:ARGX; NASDAQ:ARGX). argenx told BioCentury it has received $60 million from AbbVie thus far under the 2016...
BC Extra | Aug 22, 2018
Company News

AbbVie exercises option for argenx cancer candidate

AbbVie Inc. (NYSE:ABBV) exercised an option for exclusive, worldwide rights to develop and commercialize ARGX-115 from argenx S.E. (Euronext:ARGX; NASDAQ:ARGX). argenx told BioCentury it has received $60 million from AbbVie thus far under the 2016...
BioCentury | Jul 6, 2017
Emerging Company Profile

LAPping up TGF beta

Tilos Therapeutics Inc. aims to boost antitumor immunity by blocking TGF beta-induced production of immunosuppressive cells. By arresting TGF beta in its immature, inactive form, the company’s antibodies could be more effective than therapies that...
BC Week In Review | Apr 25, 2016
Company News

argenx, AbbVie deal

AbbVie acquired an exclusive option from argenx to license ARGX-115 , a mAb against leucine-rich repeat containing 32 ( LRRC32 ; GARP ) that is in preclinical testing to treat cancer. argenx will be responsible for R&D through...
BC Extra | Apr 22, 2016
Company News

AbbVie gets option for argenx mAb

AbbVie Inc. (NYSE:ABBV) acquired an exclusive option from argenx N.V. (Euronext:ARGX) to license ARGX-115 , a preclinical mAb against leucine-rich repeat containing 32 ( LRRC32 ; GARP ), to treat cancer. argenx will be responsible for R&D...
BC Week In Review | Mar 23, 2015
Company News

Universite catholique de Louvain, arGEN-X deal

arGEN-X exercised an exclusive option to license worldwide rights to a preclinical mAb against leucine-rich repeat containing 32 ( LRRC32 ; GARP ) from the de Duve Institute at the university. arGEN-X said the institute received an...
Items per page:
1 - 9 of 9